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ABSTRACT
A broad range of similarities between HIV-1 gp120 and human proteins-especially those participating in
immune responses-highlight gp120 as a pleiotropic protein which can influence many important func-
tions of the human immune system. The molecular mimicry that serves to the human immunodeficien-
cy virus as potent destructive arms against immune system could be the weak point we are in search of
over decades. Examples involving sequence and informational similarities of HIV-1 gp120 and immune-
related host cell proteins important for prevention and treatment
of HIV infection are presented.
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INTRODUCTION 
F
or more than three decades, molecular mimicry has been considered as an important,
contributing factor in the pathogenesis of viral infections. Virus-bearing molecular struc-
tures similar to those expressed on the surface of normal cells, could elicit the immune
response against the host proteins. Alternatively, the immune system can recognizes these
viral determinants as "self" antigens, which allows the virus to escape the immune system
surveillance. In the context of AIDS pathogenesis, some have argued over the years that the
phenomenon of the molecular mimicry could represent a significant factor in the HIV dis-
ease expression (1-6). This particularly concerns the HIV-1 envelope glycoprotein gp120.
A broad range of structural, functional, and immunological similarities between HIV-1
gp120 and human proteins, especially those participating in immune responses, highlight
this viral component as a pleiotropic protein  that can in different ways affect many impor-
tant functions of the human immune system contributing in that way to development and
progression of HIV disease. The molecular mimicry of HIV-1 gp120 also represents the
main obstacle in the development of an effective and safe AIDS vaccine (7,8). Thus, it is of
considerable interest to investigate the molecular mimicry between HIV-1 gp120 and human
proteins and the possible impacts of this phenomenon on prevention and therapy of AIDS.
HIV ENVELOPE PROTEIN AND IMMUNE-RELATED HOST MOLECULES
The general picture of HIV mimicry is particular rather then uniformly generic. The major
fraction of the reported HIV mimicry involves immune-related host proteins-HLA, Ig, com-
plement, etc. and any connection to immunopathology is suggestive. The following table
(Table 1) of mimicry claims in the literature involving gp120 and immune-related host cell
proteins sequences attempts to present the most prominent examples.
Infection by human immunodeficiency virus type 1 (HIV-1) leads to progressive destruction
of the CD4+ T-cell subset, resulting in immune deficiency and AIDS. The specific binding
of the viral external envelope glycoprotein of HIV-1, gp120, to the CD4 molecules initiates
viral entry. An essential coreceptor for HIV either CCR5 or CXCR4, both of the chemokine-
receptor family, cooperates sequentially with CD4 to facilitate HIV entry into target cells. In
spite of considerable divergence among different HIV-1 isolates, gp120 molecules pre-
served their binding tropism for the CD4 receptor, as well as its major coreceptors. That is
why a considerable interest is paid to examination of conserved regions of gp120 molecule.
The C-terminus of second conserved region of HIV-1 gp120 and the first framework region
(FR1) of the human IgG heavy chain variable region (subgroup III), VH III contain a similar
motif VQL(N/V)ES in their sequences (19,20). The nucleotide sequence GCTGGTGG,
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Table 1. Mimicry claims in the literature involving HIV envelope protein gp120 and host-cell proteins
sequencesencoding the amino acids QLV of this motif, represents the Chi signal promoting general-
ized recombination in prokayotes (21,22). Downstream from the putative Chi sequence, a
heptamer sequence, CAGTCTG, has been identified (20). Five of the seven bases in this
nucleotide sequence match the consensus recombination signal CACTGTG already found
to be involved in V-(D)-J recombination of the Ig gene (23). It is of note that a similar
sequence exists at the same position in the gp120 gene of nearly all HIV-1 isolates.
Within the VH III gene, 260 nucleotides downstream from the Chi sequence the second IgH-
specific recombination signal, TACTGTG, have been located (22). The HIV-1 gp120 gene,
downstream of the Chi-like sequence at a similar distance (260-270 nucleotides, depend-
ing on the viral isolate), contains the homologous sequence TACTGTA, representing the
putative recombination signal. This nucleotide sequence is also conserved in all HIV-1 iso-
lates. Both of the above recombination signals, whose positions are given in Figure1, have
been shown to take part in rearrangement processes in heterogonous systems.
In the frame of experimental study which succeeded (25) the complete and active Chi
recombination spot has been identified in sera of AIDS patients using a chimeric primer
consisting of the nucleotide sequence derived from the HIV-1 envelope gene coding for the
second conserved region of gp120 and the highly conserved sequence derived from the
human immunoglobulin gene coding for the VH III domain. We have demonstrated in vivo
the recombination between the HIV-1 env gene and the bacterial gene coding for the clp pro-
tease. This RT-PCR study which included 11 HIV-positive individuals. Sera were analyzed
using the PCR primers P1 (TTGGAGAGCAATGGCTAGTGA) and P3 (ATTTCGGGGTCCC-
CTCCTGA), which are derived from the 55 strongly conserved regions of the pol and env
genes and which are highly specific for HIV-1 (24), as well as the chimeric primer P2
(ATAGTACAGCTGGTGGACTCT) containing the nucleotide sequences ATAGTA and CTCT
derived from the gp120 gene domain coding for the second conserved domain (C2) and the
consensus sequence CAGCTGGTGGA derived from the human VHIII gene domain coding
for the FR1 region. In the first step of this analysis, a large fragment of the HIV genome was
amplified from all 11 HIV-positive sera by RT PCR using the primer pair P1=P3. The sub-
sequent nested RT-PCR using the primer pair P2=P3 showed in 3 out of 11 analyzed HIV
positive sera, bands corresponding to sequences of about 260-270 nucleotides long (lines
1, 2, and 3 in Figure 1a). These RT-PCR - amplified fragments correspond to the expected
site of the HIV-1 gp120 gene encoding the C-terminus of the C2 region, the entire V3 loop,
and a large portion of the C3 region. An example of RT-PCR amplification of an HIV-posi-
tive sera that does not contain the HIV subclone carrying the Chi sequence within the gp120
gene is presented in line 5, Figure 1a. Three control sera collected from HIV negative blood
donors under the same experimental conditions showed no PCR amplification. An RTPCR
corresponding to one of these three negative controls is given in Figure 1a (line 4).
The fragment obtained from one of three Chi-positive samples containing the highest
amount of the amplification product (the first line in Figure 1a), was cloned into a plasmid
vector, and the obtained clone was sequenced (Figure 1b). Scanning of the HIV database
(24.) showed that the nucleotide sequence within primers P2 and P3 does not belong to
HIV. Further analysis performed by examination of the EMBL nucleotide database (26) by
the BLASTX program revealed that the main part of this sequence represents, with high
probability, a part of the gene encoding the clp protease. The highest homology score (S)
and the lowest value of the expected frequency of chance occurrence (E) indicate that this
evolutionarily highly conserved gene with highest probability belongs to Haemophilus
influenzae (Figure 1c). The closest values of the parameters S and E in this analysis are
obtained for the clp gene from E. coli. It is important to note that both of those bacterial sys-
tems utilize the Chi recombinational stimulator (27).
As a consequence, the gp120 antigen employed as vaccine component could, through its
immunoglobulin features, influence the host immune system. Beside that, candidate AIDS
vaccines based on recombinant viruses, including vaccinia virus, Polio virus, influenza
virus, Hepatits B virus, canarypox virus, etc., that carry the HIV-1 gp120 gene are current-
ly under consideration (28). Described properties of the HIV-1 gp120 gene indicate that,
viral vectors carrying it could represent potential new pathogens with unpredictable effects
on the immune system.
HIV ENVELOPE PROTEIN AND THE IMMUNOMODULATOR VASOAC-
TIVE INTESTINAL PEPTIDE
It has been generally assumed that host factors play an important role in determining the
clinical outcome in HIV infection, since HIV disease progression varies greatly in different
individuals. In order to define these host factors, Neurath and coworkers have investigated
antibody profiles in two groups of HIV patients: those who remained healthy for at least 10
years and those who developed AIDS within 5 years of the onset of infection (29). It was
demonstrated that antibodies recognizing the peptide RSANFTDNAKTIIVQLNESVEINCTRP
(amino acids 280-306 of the envelope protein gp120 from the BH-10 isolate of HIV-1) are
significantly more prevalent in asymptomatic carriers than in AIDS patients. Based on these
results, it was concluded that absence or disappearance of detectable antibodies reacting
with the gp120-specific epitope mimicked by synthetic peptide 280-306 might represent a
possible factor contributing to the development of AIDS. For this reason it has been pro-
posed that the maintenance of a high level of these antibodies by immunotherapy based on
active immunization with antigens containing this peptide, and/or administration of the cor-
responding antibodies, should be considered as a modality for therapy of HIV-1 infection.
Molecular mimicry of HIV gp12
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Figure 1. Results of the RT-PCR study of HIV-positive and HIV-negative sera. (a) RTPCR using the
primer pair P2=P3 on total RNA from three HIV-positive sera containing HIV subclones carrying Chi
recombinational stimulator (lines 1, 2, and 3), the HIV-negative serum (line 4), and the HIV-positive
serum, which does not contain the HIV subclone carrying the Chi sequence (line 5). At the far left is
molecular size marker. (b) The nucleotide sequence obtained by cloning and sequencing of the PCR
product presented in line 1 (primers are underlined); (c) homology of the gene product corresponding
to the nucleotide sequence derived from the PCR product (Figure 1b) and the clp protease from the
H. influenzae. Note: Statistical significance is estimated under the assumption of the equivalent of one
entire reading frame of the query sequence and one entire reading frame of the database code for pro-
tein, and that significant alignments will only involve coding reading frames.Despite the presence of the strongest T cell epitope of gp120, which is active in vitro (30),
and an exposed B cell epitope (31,32), the C-terminus of the second conserved region (C2)
of HIV-1 gp120-encompassing amino acids 280-306 is not immunogenic in humans
(30,33,34). One possible conclusion drawn from these findings might be that the human
immune system is unresponsive or tolerant to this epitope. It has been postulated that
immunological tolerance to this HIV-1 gp120 domain might be the consequence of simi-
larity between the region comprising the T cell epitope and its immediate vicinity, and some
proteins participating in the human immune response. This assumption was confirmed by
the local similarity between the C-terminus of the second conserved region of HIV-1 gp120
and several human proteins, presented in Figure 2 (19,35).
Absence of the active T cell epitope within this peptide raises the question of the origin of
antibodies in human sera reacting with Neurath’s peptide. It has been postulated that these
antibodies represent autoreactive antibodies elicited by some human antigen (36).
In order to identify candidates for this autoantigen, human sequences from Swiss-Prot pro-
tein database were analyzed using the Informational Spectrum Method. This method is used
for the analyses of protein sequences by signal processing techniques. According to this
approach, protein sequences are transformed into signals by assignment of numerical val-
ues to each amino acid. These values correspond to the electron-ion interaction potential
(41), determining electronic properties of amino acids responsible for their intermolecular
interactions (42). The signal obtained is then decomposed in periodical functions by Fourier
transformation. The result is a series of frequencies and their amplitudes. The obtained fre-
quencies correspond to the distribution of structural motifs with defined physico-chemical
characteristics responsible for the biological function of the protein.
The informational spectrum calculated for the peptide 280-306 is presented in Figure 3a.
As can be seen, it contains only one characteristic pick corresponding to the frequency
F(0.218). The computer assisted search of the Swiss-Prot database revealed the vasoac-
tive intestinal peptide (VIP) as the only protein among analyzed human proteins that pos-
sesses such a spectral property (Figure 3b). Furthermore, the domain of the peptide 280-
306 with an informational spectrum most similar to VIP has been identified (Figure 3c). This
region corresponds to the sequence RSANFTDNACTIIVQLNESVEIN (denoted as the peptide
NTM) (36). It is of note that the second dominant common frequency component F(0.031)
in the informational spectra of VIP and the peptide NTM was previously identified as spec-
tral characteristic representing information that is responsible for interaction between HIV
and the CD4 receptor (43). In Figure 3d is the sequence homology between peptides VIP
and NTM. These results point at VIP as self-antigen eliciting autoantibodies that react with
peptide identified by Neurath and co-workers, and this possibility was experimentally test-
ed (37). Presence of the anti-VIP antibodies have been reported in high concentration in
sera from asthma patients (38) and in lower concentration in sera from normal healthy indi-
viduals (39,40). Affinity chromatography on agarose-bound VIP peptide to compare anti-
body binding to NTM and VIP was used. The elution profiles represented by Veljkovic et al.
(44) are in fact nearly identical, suggesting that both peptides may bind to the same frac-
tion of antibodies. The above-presented results clearly demonstrate functional and
immunological crossreactivity between HIV-1 gp120 and VIP.
As a corollary, correlation between the titer of VIP=NTM-reactive antibodies and the HIV-dis-
ease progression indicates that these antibodies may be an important factor in control of the
disease. Based on this, the possibility of applying passive immunization, based on the
VIP=NTM-reactive antibodies, as a therapy for HIV disease was taken in consideration (22).
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Figure 2. Sequence homologies between the C-terminus of the second conserved region of HIV-1
gp120 and human proteins. The asterisk (*) indicates residues that are identical, and the sign (+)
indicates a conservative change (6)
Figure 3. Spectral and sequence similarities between the peptide 280-306 derived from HIV-1 gp120,
the peptide NTM, and VIP. (a) The informational spectrum (IS) of the peptide 280-306, (b) IS of VIP,
(c) IS of the peptide NTM, and (d) sequence homology between the peptide NTM and VIP. For each
spectrum, the abscissa represents the frequencies from the Fourier transform of the sequence of the
electron-ion interaction potential corresponding to the amino acid sequence. The lowest frequency is
0.0 and the highest is 0.5. The ordinate represents amplitudes, in arbitrary units, corresponding to
each frequency component of the spectrum. (d) The * indicates residues that are identical, and the
plus sign indicates a conserved change.CONCLUDING REMARKS
The presented examples shows that the molecular mimicry that serves to the human
immunodeficiency virus as a powerful destructive arms against immune system of the host
could be the weak point we are looking for over decades. Immediately after the discovery
of the human immunodeficiency virus (HIV), development of AIDS vaccine became a chal-
lenge for scientists worldwide.
During the past 20 years, the pendulum of opinion in the HIV-1 vaccine field has swung
between two extremes, initially favoring the induction of antibodies only, and subsequently
favoring the induction of cell-mediated immune responses only. At present, the consensus
seems to be that induction of both humoral and cellular immunity by an HIV-1 vaccine will
be required to achieve maximum protection. One obstacle to the development of an effec-
tive HIV-1 vaccine has been the difficulty in inducing broadly reactive, potent antibodies with
protective functions. Defining epitopes and designing immunogens that will induce these
antibodies is one of the main challenges that currently confront the HIV-1 vaccine field.
A broad range of structural, functional, and immunological similarities between HIV-1
gp120 and human proteins-especially those participating in immune responses- highlight
gp120 as a pleiotropic protein which can, in different ways, affect many important functions
of the human immune system.
This situation opens the fundamental question: is a safe and effective, preventive AIDS vac-
cine possible at all, or is its current lack only the consequence of our incomplete knowl-
edge?
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